Thanks for subscribing!
Ymmunobio to Present at the Annual Meeting of the Association for Cancer Immunotherapy (CIMT)
Ymmunobio Appoints New Chief Operating Officer
Ymmunobio Accepted into Innosuisse Core Coaching
Dr. Katrin Rupalla Interviewed by Global Business Reports
Drug Discovery & Development
Fierce Biotech: Appointment of Michel Janicot
Ymmunobio get ownership rights to NPTXR antibodies. Read more here:
Michel Janicot will serve in the newly created position of chief development officer.
Ymmunobio adds to executive team.
Read more here: https://www.biopharmadive.com/press-release/20230109-ymmunobio-appoints-dr-michel-janicot-as-chief-development-officer/